Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: John Patterson who wrote (248)	7/28/1998 11:06:00 PM
From: aknahow	Read Replies (1) \| Respond to of 712

I was disappointed that Merck raised their dividend and announced a share buy-back but, in time redeployment of their resources will have an impact on biotecks. Did you see the press release from the Informed Investors conference showing the value of Merck being many billions more more than 180 biotech companies which have many more products in clinical trials? Have written a few Oct. puts on CORR @ $12.5. I would not mind owning at this price less the premium. They were done a month or so ago when the market price was lower and the time premium higher. CORR has been a strange story. My only involvement has been with selling puts and covered calls. Never expected to be able to start the whole process all over.

To: John Patterson who wrote (248)	7/29/1998 2:45:00 AM
From: G-MAN	Read Replies (1) \| Respond to of 712

John, Just keep taking shares away from the people who are selling them. In the past two months, COR has received at least 2 - 3 brokerage house recommendations, the Medical Technology Stock Letter has added it to their recommended list by insisting that they are extremely undervalued and the CTSL has been recommending it in the same manner. I've waited for quite some time to buy at these prices. I bought back when it dipped to $12.25 and I bought more in the low $14's. I'll keep adding to my position as I can afford it. At some point, and I do not know when, the investment community WILL wake-up to the companies in the biotech arena. I feel that this day is sooner then later. The company has $84 million in cash and a potential $200 - $300 million in revenue product approved. These are just my thoughts. Good Luck! Jerry